FAQ: AXIM Biotechnologies and VisionPlus South Korea Distribution Agreement for TearScan® Diagnostics
Summary
AXIM Biotechnologies has entered an exclusive distribution agreement with VisionPlus Corp. to market TearScan® Lactoferrin and IgE diagnostic tests in South Korea, enabling quantitative point-of-care tear analysis to improve diagnosis and treatment of dry eye disease and ocular allergies.
What is the main announcement in this content?
AXIM Biotechnologies has signed an exclusive distribution agreement with VisionPlus Corp. to market and distribute AXIM’s TearScan® Lactoferrin Test for aqueous-deficient dry eye detection and TearScan® IgE Test for ocular allergy throughout South Korea.
Why is this partnership significant for patients and clinicians in South Korea?
This collaboration brings quantitative tear diagnostics directly to clinicians, improving diagnostic precision and enabling more personalized care for patients suffering from dry eye disease and ocular allergy, while creating a comprehensive diagnostic and treatment ecosystem.
How will the TearScan® diagnostic tests be distributed in South Korea?
VisionPlus receives exclusive rights to distribute both TearScan® tests supported by the I-Peak digital reader across South Korea, leveraging their established network of ophthalmology clinics, hospitals, and specialty Dry Eye Centers.
What regulatory steps are involved in bringing these tests to the Korean market?
The companies will collaborate on Korean MFDS registration with simultaneous submissions for both assays, with VisionPlus leading local compliance, regulatory coordination, and commercialization efforts.
How long is the distribution agreement valid?
The initial term is one year, with automatic one-year renewals for an additional four years tied to annual sales milestones.
What specific conditions do the TearScan® tests help diagnose?
The TearScan® Lactoferrin Test detects aqueous-deficient dry eye (ADDE), while the TearScan® IgE Test diagnoses ocular allergy, helping clinicians differentiate between aqueous-deficient dry eye, evaporative dry eye, and allergic conjunctivitis.
What are the key benefits of AXIM’s TearScan® diagnostic platform?
The platform provides quantitative, point-of-care tear biomarker analysis in minutes using a small tear sample, delivering precise measurements with laboratory-grade accuracy in office settings to enhance diagnostic confidence and treatment outcomes.
What role does VisionPlus play in the Korean eye care market?
VisionPlus is a Korean distributor specializing in ophthalmic diagnostic and therapeutic technologies, serving hospitals, specialty eye clinics, and ophthalmology practices across South Korea with established Dry Eye Clinics and a commitment to advancing ocular health.
Who retains manufacturing and intellectual property rights for the TearScan® products?
AXIM will retain manufacturing control, intellectual-property ownership, and provide regulatory and technical support for market entry and ongoing product quality compliance.
Who can be contacted for more information about this announcement?
Media inquiries should be directed to Catalina Valencia, President of AXIM Biotechnologies, at [email protected] or (858) 256-5132.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire
Article Control ID: 262006